Apixaban to prevent blood clots after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You had a heart attack affecting the front wall of your heart (called an anterior STEMI)
- Your heart's main pumping chamber (left ventricle) is very weak, with an ejection fraction below 35% and an area that does not move normally
- You do not already have a blood clot in your heart
- You do not have severe kidney disease, a recent stroke, or a bleeding disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
This trial compares the blood thinner apixaban to warfarin for treating blood clots in the main pumping chamber of the heart (left ventricle). The goal is to see which medicine is better at preventing strokes and other complications.
This trial tests if patients with a blood clot in the left ventricle can safely stop blood thinner (Apixaban) after at least 3 months, instead of taking it longer. It may help people with no additional risks avoid extra medication.
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
Hear when a new Left Ventricular Thrombus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.